Pharmacokinetic profile of tigecycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrations

被引：68

作者：

Sun, HK

Ong, CT

Umer, A

Harper, D

Troy, S

Nightingale, CH

Nicolau, DP

机构：

[1] Hartford Hosp, Ctr Antiinfect Res & Dev, Ishikari, Hokkaido 06102, Japan

[2] Hartford Hosp, Div Infect Dis, Ishikari, Hokkaido 06102, Japan

[3] Univ Connecticut, Sch Med, Farmington, CT USA

[4] Wyeth Ayerst Res, Collegeville, PA USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2005年 / 49卷 / 04期

关键词：

D O I：

10.1128/AAC.49.4.1629-1632.2005

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

The pharmacokinetics of tigecycline, when given as a 100-mg loading dose followed by 50 mg every 12 h, were determined in serum and blister fluid. The peak tigecycline concentration and half-life in serum were greater than those in blister fluid. Tigecycline penetrates into blister fluid well, with a mean penetration rate of 74%.

引用

收藏

页码：1629 / 1632

页数：4

相关论文

共 19 条

[1] In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain [J].

Betriu, C ;

Rodríguez-Avial, I ;

Sánchez, BA ;

Gómez, M ;

Alvarez, J ;

Picazo, JJ .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (03) :892-895

[2] In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum β-lactamases [J].

Biedenbach, DJ ;

Beach, ML ;

Jones, RN .

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2001, 40 (04) :173-177

[3]

Eron Lawrence J., 2003, Journal of Antimicrobial Chemotherapy, V52, pi3

[4]

FILE TM, 1995, AM J SURG, V169, pS27

[5] Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates [J].

Gales, AC ;

Jones, RN .

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2000, 36 (01) :19-36

[6]

GALES AC, 2003, 43 INT C ANT AG CHEM, P207

[7] Oritavancin and tigecycline: Investigational antimicrobials for multidrug-resistant bacteria [J].

Guay, DRP .

PHARMACOTHERAPY, 2004, 24 (01) :58-68

[8] Antimicrobial susceptibility of community-acquired respiratory tract pathogens in North America in 1999-2000: findings of the PROTEKT surveillance study [J].

Hoban, D ;

Waites, K ;

Felmingham, D .

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2003, 45 (04) :251-259

[9] Antipneumococcal activities of GAR-936 (a new glycylcycline) compared to those of nine other agents against penicillin-susceptible and -resistant pneumococci [J].

Hoellman, DB ;

Pankuch, GA ;

Jacobs, MR ;

Appelbaum, PC .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (04) :1085-1088

[10] Epidemiology and antibiotic susceptibility of bacteria causing skin and soft tissue infections in the USA and Europe: a guide to appropriate antimicrobial therapy [J].

Jones, ME ;

Karlowsky, JA ;

Draghi, DC ;

Thornsberry, C ;

Sahm, DF ;

Nathwani, D .

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2003, 22 (04) :406-419